LB Pharmaceuticals Inc Common Stock - LBRX - Fundamentals

Feel free to try out our engine!Whenever you're ready, pick a plan!

Best Investments/trading ideas for the weekJoin our free webinar on September23,2026.

Insider Tracker is here!

‌
‌

‌

Let's get started...

‌

Breakdown	2022 12/31	2023 12/31	2024 12/31	2025 12/31	TTM
REVENUE	0	0	0	0	--	📊
Revenue Growth (1Y)	--	--	--	--	--	📊
Revenue Growth (5Y)	--	--	--	--	--	📊
Revenue Growth (10Y)	--	--	--	--	--	📊
Cost of Revenue	0	0	0	0	--	📊
Cost of Revenue Growth (1Y)	--	--	--	--	--	📊
Cost of Revenue Growth (5Y)	--	--	--	--	--	📊
Cost of Revenue Growth (10Y)	--	--	--	--	--	📊
Gross Profit	0	0	0	0	--	📊
Gross Profit Growth (1Y)	--	--	--	--	--	📊
Gross Profit Growth (5Y)	--	--	--	--	--	📊
Gross Profit Growth (10Y)	--	--	--	--	--	📊
Operating Expenses	3	11	65	30	95	📊
Operating Expenses Growth (1Y)	--	+304.98%	+469.88%	-53.10%	+212.63%	📊
Operating Expenses Growth (5Y)	--	--	--	--	--	📊
Operating Expenses Growth (10Y)	--	--	--	--	--	📊
Sell General Administrative	1	4	14	14	25	📊
Research and Development	1	8	51	17	70	📊
Other Income Expenses	0	0	0	0	1	📊
EBITDA	-12	-1	-63	-25	-88	📊
EBITDA Growth (1Y)	--	+88.15%	-4260.55%	+60.51%	-252.25%	📊
EBITDA Growth (5Y)	--	--	--	--	--	📊
EBITDA Growth (10Y)	--	--	--	--	--	📊
Depreciation and Amortization	0	0	0	0	--	📊
Operating Income	-3	-11	-65	-30	-95	📊
Operating Income Growth (1Y)	--	-304.98%	-469.88%	+53.10%	-212.90%	📊
Operating Income Growth (5Y)	--	--	--	--	--	📊
Operating Income Growth (10Y)	--	--	--	--	--	📊
Interest Expense	2	5	0	0	--	📊
Pre Tax Income	-14	-6	-63	-25	-86	📊
Tax Provision	0	0	0	0	--	📊
NET INCOME	-14	-6	-63	-25	-86	📊
Net Income Growth (1Y)	--	+56.27%	-905.61%	+60.06%	-239.95%	📊
Net Income Growth (5Y)	--	--	--	--	--	📊
Net Income Growth (10Y)	--	--	--	--	--	📊
Basic EPS	-4.05	-1.77	-17.83	-1	-2.97	📊
Diluted EPS	-4.05	-1.77	-17.83	-1	-2.97	📊
Basic Average Shares	4	4	4	25	27	📊
Diluted Average Shares	4	4	4	25	27	📊

Breakdown	2022 12/31	2023 12/31	2024 12/31	2025 12/31	TTM
REVENUE	0	0	0	0	--	📊
Revenue Growth (1Y)	--	--	--	--	--	📊
Revenue Growth (5Y)	--	--	--	--	--	📊
Revenue Growth (10Y)	--	--	--	--	--	📊
Cost of Revenue	0	0	0	0	--	📊
Cost of Revenue Growth (1Y)	--	--	--	--	--	📊
Cost of Revenue Growth (5Y)	--	--	--	--	--	📊
Cost of Revenue Growth (10Y)	--	--	--	--	--	📊
Gross Profit	0	0	0	0	--	📊
Gross Profit Growth (1Y)	--	--	--	--	--	📊
Gross Profit Growth (5Y)	--	--	--	--	--	📊
Gross Profit Growth (10Y)	--	--	--	--	--	📊
Operating Expenses	3	11	65	30	95	📊
Operating Expenses Growth (1Y)	--	+304.98%	+469.88%	-53.10%	+212.63%	📊
Operating Expenses Growth (5Y)	--	--	--	--	--	📊
Operating Expenses Growth (10Y)	--	--	--	--	--	📊
Sell General Administrative	1	4	14	14	25	📊
Research and Development	1	8	51	17	70	📊
Other Income Expenses	0	0	0	0	1	📊
EBITDA	-12	-1	-63	-25	-88	📊
EBITDA Growth (1Y)	--	+88.15%	-4260.55%	+60.51%	-252.25%	📊
EBITDA Growth (5Y)	--	--	--	--	--	📊
EBITDA Growth (10Y)	--	--	--	--	--	📊
Depreciation and Amortization	0	0	0	0	--	📊
Operating Income	-3	-11	-65	-30	-95	📊
Operating Income Growth (1Y)	--	-304.98%	-469.88%	+53.10%	-212.90%	📊
Operating Income Growth (5Y)	--	--	--	--	--	📊
Operating Income Growth (10Y)	--	--	--	--	--	📊
Interest Expense	2	5	0	0	--	📊
Pre Tax Income	-14	-6	-63	-25	-86	📊
Tax Provision	0	0	0	0	--	📊
NET INCOME	-14	-6	-63	-25	-86	📊
Net Income Growth (1Y)	--	+56.27%	-905.61%	+60.06%	-239.95%	📊
Net Income Growth (5Y)	--	--	--	--	--	📊
Net Income Growth (10Y)	--	--	--	--	--	📊
Basic EPS	-4.05	-1.77	-17.83	-1	-2.97	📊
Diluted EPS	-4.05	-1.77	-17.83	-1	-2.97	📊
Basic Average Shares	4	4	4	25	27	📊
Diluted Average Shares	4	4	4	25	27	📊

LB Pharmaceuticals Inc Common Stock - LBRX - Fundamentals - Financial Statements